Trial Profile
Phase 1 Study of Combination Osimertinib, Platinum, Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers With Concurrent RB1 and TP53 Alterations
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Etoposide (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 12 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Jul 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2024.
- 01 Jul 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2024.